Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 1000+ Conferences, 1000+ Symposiums and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series Ltd: World’s leading Event Organizer

Back

Ramaiah Muthyala

Ramaiah Muthyala

Doctor
University of Minnesota
USA

Biography

Dr. Ramaiah Muthyala holds Ph.D (Natural Products), Ph.D. (Heterocyclic Chemistry) and MBA (International Management). He is Fellow of Royal Society of Chemistry. Among other awards, he received SC Amita award from the Indian Chemical Society. He has been editor or and coeditor of books, book chapters and has been in editorial boards of ARKIVOC, Mini-reviews in Medicinal Chemistry. For the last 12 years, Dr. Muthyala has been at the University of Minnesota where he was Associate Director, Center for Drug Design, and Associate Director (pre-clinical development) Center for Orphan Drug Research. He is also Associate Professor, Department of Experimental Clinical Pharmacology and Adjunct Professor, Department of Medicine. His research interests focused in rare diseases - the discovery and development of therapeutics for drug resistant bacterial infections, neurological diseases such as SCA1 and hemoglobinopathy such sickle cell disease. In his research, drug repositioning takes major emphasis to discovering drug leads.

Research Interest

The vision of our research program is to translate biological and chemical information into leads to drug-like molecules and optimize the lead small molecules to drug molecules using synthetic organic chemistry. The drug discovery will be combined with structure information obtained from ligand-protein structures, enzyme data derived from computational, modeling and biological experiments. The potential for speedy optimization of drug discovery, selective and carefully designed combinatorial small libraries along with rapid, sensitive and specific assay procedures are being explored. Natural products with desired biological activity at nanomolar range are considered as informed lead compounds for further development into drug candidates.